Bioleaders Corporation - Asset Resilience Ratio

Latest as of June 2026: 0.31%

Bioleaders Corporation (142760) has an Asset Resilience Ratio of 0.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Bioleaders Corporation's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩100.00 Million

≈ $67.77K USD Cash + Short-term Investments

Total Assets

₩32.47 Billion

≈ $22.01 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Bioleaders Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 142760 asset base.

Liquid Assets Composition Over Time

This chart breaks down Bioleaders Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Bioleaders Corporation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩100.00 Million	0.31%
Total Liquid Assets	₩100.00 Million	0.31%

Asset Resilience Insights

Limited Liquidity: Bioleaders Corporation maintains only 0.31% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Bioleaders Corporation Industry Peers by Asset Resilience Ratio

Compare Bioleaders Corporation's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Xizang Haisco Pharmaceutical Group Co Ltd SHE:002653	Biotechnology	1.69%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.12%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	23.94%
ChemPartner PharmaTech Co Ltd SHE:300149	Biotechnology	1.67%
Inventiva S.A PA:IVA	Biotechnology	52.73%
Yantai Zhenghai Bio-Tech Co Ltd SHE:300653	Biotechnology	59.25%

Annual Asset Resilience Ratio for Bioleaders Corporation (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Bioleaders Corporation.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.48%	₩206.04 Million ≈ $139.63K	₩42.61 Billion ≈ $28.87 Million	-54.04pp
2024-12-31	54.52%	₩33.94 Billion ≈ $23.00 Million	₩62.25 Billion ≈ $42.19 Million	+15.12pp
2023-12-31	39.41%	₩19.34 Billion ≈ $13.11 Million	₩49.07 Billion ≈ $33.26 Million	+17.25pp
2022-12-31	22.15%	₩32.88 Billion ≈ $22.28 Million	₩148.42 Billion ≈ $100.58 Million	-12.49pp
2021-12-31	34.64%	₩65.42 Billion ≈ $44.33 Million	₩188.85 Billion ≈ $127.98 Million	+12.71pp
2020-12-31	21.93%	₩41.81 Billion ≈ $28.34 Million	₩190.69 Billion ≈ $129.23 Million	-8.32pp
2019-12-31	30.25%	₩44.80 Billion ≈ $30.36 Million	₩148.11 Billion ≈ $100.37 Million	+3.65pp
2018-12-31	26.60%	₩40.77 Billion ≈ $27.63 Million	₩153.29 Billion ≈ $103.88 Million	-42.29pp
2017-12-31	68.88%	₩25.88 Billion ≈ $17.54 Million	₩37.58 Billion ≈ $25.46 Million	+6.92pp
2016-12-31	61.96%	₩13.39 Billion ≈ $9.08 Million	₩21.61 Billion ≈ $14.65 Million	--

pp = percentage points

About Bioleaders Corporation

KQ:142760 Korea Biotechnology

Market Cap

$6.67 Million

₩9.85 Billion KRW

Market Cap Rank

#28091 Global

#2064 in Korea

Share Price

₩467.00

Change (1 day)

-0.64%

52-Week Range

₩349.00 - ₩1850.00

All Time High

₩24990.00